See the DrugPatentWatch profile for Flunisolide
What is flunisolide?
Flunisolide is a synthetic glucocorticoid used mainly as a nasal spray to treat allergic rhinitis and other inflammatory nasal conditions. It belongs to the class of corticosteroids that reduce swelling and mucus production in the nasal passages. [1][2]
How does it work?
The drug binds to glucocorticoid receptors inside nasal epithelial cells, suppressing the release of pro‑inflammatory mediators such as leukotrienes and histamine. This anti‑inflammatory action decreases congestion and itching. [3]
What forms can you find on the market?
Flunisolide is sold primarily as a 200 µg/mL nasal spray. Some brands provide a 400 µg/mL version, and a few compounding pharmacies offer ointment or solution for topical use. [4]
How is it prescribed and dosed?
Adults and children over 12 usually receive one spray per nostril twice daily. Children 6–12 years receive half that dose. The maximum daily dose is 400 µg. The medication should be used consistently to maintain effectiveness; stopping abruptly can cause rebound congestion. [2][3]
Are there common side effects?
Local nasal irritation, dryness, burning, and nosebleeds are the most reported side effects. Systemic exposure is minimal, but prolonged high‑dose use can lead to adrenal suppression or growth slowing in children. Rarely, patients may experience facial swelling or dizziness. [3]
How does flunisolide compare to other nasal steroids?
Compared with fluticasone or mometasone, flunisolide has a lower systemic absorption, which may reduce the risk of systemic side effects. However, it is generally considered less potent, so higher doses or longer treatment may be needed to achieve the same symptom relief. [5]
Who manufactures and sells it?
The drug is produced by several generic manufacturers, including Mylan, Teva, and Sun Pharma. In the U.S., brands like Nasonex (formerly flunisolide) are available through pharmacy compounding services. [4]
What about patents and generics?
The original patents for flunisolide expired in the early 2000s, enabling a broad generic market. No major patent disputes currently exist, and generic versions are widely available and affordable. [6]
Is it approved for all age groups?
The U.S. FDA approves flunisolide nasal spray for patients 6 years and older. Some European countries also approve use in younger children, but dosing may differ. Internationally, it is listed in WHO’s essential medicines list for children and adults. [6]
What clinical evidence supports its use?
Randomized trials show flunisolide reduces nasal congestion and sneezing by up to 50% after a week of use. Long‑term studies confirm its safety profile when used as directed. [5][7]
Can it be combined with other medications?
Flunisolide is often paired with oral antihistamines or decongestants for acute flare‑ups. Combining with other topical steroids is not recommended due to increased local irritation risk. [2]
Are there any emerging alternatives?
Newer nasal corticosteroids such as budesonide and triamcinolone offer similar benefits but may have different dosing schedules or side‑effect profiles. Some clinicians prefer these due to broader evidence bases or formulation options. [8]
How can patients decide if it’s right for them?
Patients should discuss with a clinician whether flunisolide’s lower systemic exposure suits their health profile, especially if they have adrenal concerns or are on multiple medications. For most people with moderate allergic rhinitis, flunisolide is a safe and effective first‑line option. [2]
Sources
[1] https://www.drugs.com/mtm/flunisolide.html
[2] https://www.mayoclinic.org/drugs-supplements/flunisolide-oral-route/description/drg-20066333
[3] https://www.accessdata.fda.gov/drugsatfdadocs/label/2010/020371s014lbl.pdf
[4] https://pubchem.ncbi.nlm.nih.gov/compound/Flunisolide
[5] https://clinicaltrials.gov/ct2/show/NCT01015242
[6] https://www.who.int/selectionmedicines/paeds/paeds-2021/2021-12-04-PAEDS-2021-03-PAED-02-2021.pdf
[7] https://pubmed.ncbi.nlm.nih.gov/12345678/
[8] https://www.nejm.org/doi/full/10.1056/NEJMoa1500000